The combination of hypomethylating agents and BCL2 inhibitors is a standard treatment for acute myeloid leukemias, which can harbor an IDH-2 mutation. Further studies are needed for IDH-mutant gliomas, for which treatment options are still limited. This evidence concerns the gene IDH2 and central nervous system cancer.